Natalizumab treatment promotes activation and differentiation of peripheral B cells in multiple sclerosis

被引：0
|
作者：
Husseini, L. [1 ]
Seeger, I. [2 ]
Rowold, C. [1 ]
Brueck, W. [2 ]
Weber, M. [1 ,2 ]
机构：
[1] Univ Med Ctr, Dept Neurol, Gottingen, Germany
[2] Univ Med Ctr, Inst Neuropathol, Gottingen, Germany
来源：
MULTIPLE SCLEROSIS JOURNAL | 2018年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1217
引用
收藏
页码：689 / 690
页数：2
相关论文
共 50 条
  • [31] Considerations on Discontinuing Natalizumab for the Treatment of Multiple Sclerosis
    Berger, Joseph R.
    Centonze, Diego
    Comi, Giancarlo
    Confavreux, Christian
    Cutter, Gary
    Giovannoni, Gavin
    Gold, Ralf
    Hartung, Hans-Peter
    Lublin, Fred
    Miravalle, Augusto
    Montalban, Xavier
    O'Connor, Paul
    Olsson, Tomas
    Polman, Chris H.
    Stuve, Olaf
    Wolinsky, Jerry S.
    Ziemssen, Tjalf
    ANNALS OF NEUROLOGY, 2010, 68 (03) : 409 - 411
  • [32] Biomarkers for monitoring natalizumab treatment in multiple sclerosis
    Bringeland, G. H.
    Vedeler, C. A.
    Myhr, K. M.
    Gavasso, S.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 901 - 901
  • [33] Treatment with Natalizumab in patients with multiple sclerosis is associated with increased numbers of circulating CD34+cells in the peripheral blood
    Zohren, Fabian
    Czibere, Akos
    Toutzaris, Diamandis
    Hartung, Hans-Peter
    Bruns, Ingmar
    Haas, Rainer
    BLOOD, 2007, 110 (11) : 304B - 304B
  • [34] Peripheral blood mononuclear cells immunophenotyping in multiple sclerosis patients after natalizumab treatment in comparison with immunoablation with autologous hematopoietic stem cells transplantation treatment
    Krasulova, E.
    Havrdova, E.
    Mareckova, H.
    Vankova, Z.
    8TH INTERNATIONAL CONGRESS OF NEUROIMMUNOLOGY, 2006, : 89 - 92
  • [35] Effect of natalizumab on B lymphocytes in patients with multiple sclerosis
    Putzki, N.
    Kumar, M.
    Grosse-Wilde, H.
    Kreuzfelder, E.
    MULTIPLE SCLEROSIS, 2007, 13 : S158 - S158
  • [36] Natalizumab promotes anti-inflammatory and repair effects in multiple sclerosis
    Lereim, Ragnhild Reehorst
    Nytrova, Petra
    Guldbrandsen, Astrid
    Havrdova, Eva Kubala
    Myhr, Kjell-Morten
    Barsnes, Harald
    Berven, Frode S.
    PLOS ONE, 2024, 19 (03): : 1 - 23
  • [37] Natalizumab in the treatment of patients with multiple sclerosis -: First experience
    Mareckova, Helena
    Havrdova, Eva
    Krasulova, Eva
    Vankova, Zdenka
    Koberova, Michaela
    Sterzl, Ivan
    AUTOIMMUNITY, PT B: NOVEL APPLICATIONS OF BASIC RESEARCH, 2007, 1110 : 465 - 473
  • [38] The role of natalizumab in the treatment of multiple sclerosis: benefits and risks
    Singer, Barry A.
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2017, 10 (09) : 327 - 336
  • [39] Risk Acceptance in Multiple Sclerosis Patients on Natalizumab Treatment
    Tur, Carmen
    Tintore, Mar
    Vidal-Jordana, Angela
    Bichuetti, Denis
    Nieto Gonzalez, Pablo
    Jesus Arevalo, Maria
    Arrambide, Georgina
    Anglada, Elisenda
    Galan, Ingrid
    Castillo, Joaquin
    Jordi Rio, Carlos Nos
    Isabel Martin, Maria
    Comabella, Manuel
    Sastre-Garriga, Jaume
    Montalban, Xavier
    PLOS ONE, 2013, 8 (12):
  • [40] An audit evaluation of treatment with natalizumab in people with multiple sclerosis
    Holland, G.
    McDonald, K. R.
    Talbot, P.
    Rog, D. J.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S441 - S441
12345